From the Department of Cardiovascular Medicine,
University of Oxford, Wellcome Trust Centre for Human Genetics, Henry
Wellcome Building of Genomic Medicine, Roosevelt Drive, Oxford OX3 7BN,
and § Cancer Research UK, Molecular Oncology Unit,
Hammersmith Hospital, London W12 0HS, United Kingdom
Received for publication, August 9, 2002, and in revised form, January 10, 2003
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
The transcriptional co-activators and
histone acetyltransferases p300/CREB-binding protein (CBP) interact
with CITED2, a transcription factor AP-2 (TFAP2) co-activator.
p300/CBP, CITED2, and TFAP2A are essential for normal neural tube and
cardiac development. Here we show that p300 and CBP co-activate TFAP2A
in the presence of CITED2. TFAP2A transcriptional activity was modestly
impaired in p300+/ Recruitment of the transcriptional co-activators p300 and
CREB1-binding protein (CBP)
to gene promoters by DNA-bound transcription factors activates gene
transcription (reviewed in Ref. 1). In addition to functioning as
bridging molecules between transcription activators and the general
transcriptional machinery, CBP and p300 have intrinsic histone
acetyltransferase (HAT) activity and very likely play a role in
chromatin remodeling. Acetylation of transcription factors by p300 and
CBP also modulates their activity (2).
Mice lacking p300 or CBP develop neural tube closure and cardiac and
skeletal defects (3-5). Mutation of a single allele of CBP in humans
causes Rubinstein-Taybi syndrome, characterized by mental retardation
and cardiac, cranio-facial, and skeletal malformations (6). p300 and
CBP have overlapping functions, as indicated by the fact that mice
lacking one allele of p300 and one allele of CBP (double heterozygotes)
show early embryonic lethality, with defects in neural tube closure.
However, they also have clearly distinct functions, as well. For
instance, retinoid receptor function requires p300 rather than CBP,
whereas CREB function requires CBP rather than p300 (5, 7). Moreover, the plant homeodomain finger of p300 but not CBP is essential for
histone acetyltransferase activity (8).
The first cysteine-histidine-rich (CH1) region of p300/CBP directly
binds members of a recently identified gene family termed CITED
(CBP/p300 interacting
transactivators with ED-rich termini) (9-12). Members of this family include CITED1 (also known as Msg1) (13), CITED2 (splice isoforms known as Mrg1 or p35srj (9, 13-15)), and
CITED4 (16, 17). A key feature of this family is a conserved 32-amino
acid sequence motif at the C terminus that is necessary and sufficient
for binding p300/CBP (9, 16). CITED proteins do not appear to bind DNA
directly but function as transcriptional co-activators (11,
16-19).
CITED2 is a ubiquitously expressed growth factor and hypoxia-inducible
gene with oncogenic properties (9, 15). Nearly all cellular CITED2 is
complexed physically with p300/CBP, indicating that it binds with high
affinity (9). Mice lacking CITED2 have abnormal cardiac, adrenal,
neural tube, and cranial ganglia (19-21). CITED2 (and CITED4) interact
physically with and co-activate isoforms A, B, and C of the DNA binding
transcription factor AP-2 (TFAP2) (16, 19). CITED2 is necessary for
TFAP2 transactivation, and Cited2 The similar phenotypes observed in mice lacking p300/CBP and TFAP2A/B
led us to hypothesize that p300 and CBP may function as TFAP2
co-activators. Here we describe, for the first time, physical and
functional interactions between TFAP2 isoforms and p300/CBP. Our
results suggest a model wherein interactions among TFAP2A, CITED2, and
p300/CBP are necessary for TFAP2A-mediated transcriptional activation
and for normal neural tube and cardiac development.
Standard molecular biology protocols were used for all
procedures (28). Reagents were from Sigma unless otherwise indicated.
Plasmids--
CMV-TFAP2A, CMV-TFAP2B, and CMV-TFAP2C and
CMV-CITED2 were described previously (19). RSV-TFAP2A and
RSV-TFAP2A Antibodies--
RK5C1 (Santa Cruz Biotechnology, Inc.) is a
monoclonal antibody against GAL4-DBD. Anti-CITED2 polyclonal antibody
has been described previously (9). PAB419 and 9E10 are monoclonal
antibodies against SV40 Tag and the myc epitope, respectively, and were
gifts from Jim DeCaprio (Dana-Farber Cancer Institute, Boston, MA). Mouse monoclonal 12CA5 antibody was used to detect hemagglutinin-tagged proteins. Anti-tubulin antibody was obtained from Sigma (T-5293). Anti-TFAP2A (sc-184X) and anti-proliferating cell nuclear antigen (sc-56) antibodies were obtained from Santa Cruz Biotechnology, Inc.
Western blots were performed as described previously (9).
Cells--
p300 and CBP heterozygote mice (5) were gifts from
David Livingston (Dana-Farber Cancer Institute, Boston, MA). Mouse
embryonic fibroblasts (MEFs) from 15.5-day-old p300 heterozygote or CBP heterozygote embryos, and their wild-type littermate controls were
generated as described (34) and genotyped using allele-specific primers. Hep3B, HepG2, and U2-OS cells were obtained from ATCC.
Immunoprecipitations--
U2-OS cells were plated at 2 × 106 cells per p100 plate and transfected the following day
with 10 µg of the indicated plasmids using FuGENE 6 (Roche Molecular
Biochemicals). Cells were lysed, and immunoprecipitations were
performed as described (9) in buffer containing 50 mM
Tris-HCl, pH 8.0, 150 mM NaCl, 0.5% Nonidet P-40, 0.5 mM EDTA, protease and phosphatase inhibitors (Complete protease inhibitor (Roche Molecular Biochemicals), 1 mM
phenylmethylsulfonyl fluoride, 0.5 mM sodium orthovanadate,
5 mM sodium fluoride), and 1 mM DTT.
Immunostaining--
Hep3B cells were plated at 2 × 105 cells per six-well plate and transfected the following
day with 2 µg of CMV-p300-myc or CMV-p300(D1399Y)-myc and 0.5 µg of
CMV-CITED2 or control vector using FuGENE 6 (Roche Molecular
Biochemicals). 0.5 µg of CMV-TFAP2A or the control vector were also
co-transfected. Immunostaining was performed 48 h after the
transfection using anti-TFAP2A and anti-CITED2 polyclonal antibodies at
1:150 dilution, essentially as described (9). The anti-myc 9E10
monoclonal antibody was used as neat culture supernatant. Nuclei were
counterstained with TOPRO (Molecular Probes). Cells were mounted in
Vectamount (Vector) and were visualized using a Bio-Rad MRC 1024 confocal microscope. Data from TOPRO (blue), rhodamine (red), and
fluorescein isothiocyanate (green) channels were accumulated sequentially.
Transfections and Luciferase Assays--
Cells were plated in
24-well plates at 2.5 × 104 cells per well and were
transfected in duplicate the following day using FuGENE 6 (Roche
Molecular Biochemicals) or Transfast reagent (Promega). CMV-lacZ (100 ng) or pRL-CMV were co-transfected in all experiments. Firefly
luciferase and Far Western Assays--
The TFAP2 variants used as probes in Far
Western (FW) assays were translated in vitro using the TNT
coupled reticulocyte lysate system (Promega). The proteins were labeled
radioactively in 100-µl reactions using
L-[35S]methionine/L-[35S]cysteine
Pro-mix (Amersham Biosciences). Unincorporated amino acids were removed
using Microcon-MWCO 3000 (Amicon) centrifugal filter devices, according
to the manufacturer's instructions, and the buffer was changed
simultaneously to FW buffer (25 mM Tris-HCl, pH 7.5, 100 mM KCl, 5 mM MgCl2, 0.1% Tween 20, 5% glycerol, 1 mM DTT, Complete protease inhibitor mix
(Roche Molecular Biochemicals). The successful synthesis and
purification of the probes were verified by SDS-PAGE and
autoradiography; all the protein probes used were synthesized to a
comparable efficiency. Assays were performed against a Yeast Two-hybrid Assays--
SFY526 yeast were transformed
simultaneously with full-length CITED2 cloned into pGAD424 and TFAP2C
constructs cloned into pGBT9 as described previously (33). Liquid
Preparation of Nuclear Extracts and Electrophoretic Mobility
Shift Assays--
Hep3B cells were plated at 2 × 106
cells per p100 plate and transfected the following day with 15 µg of
CMV-p300-myc or CMV-p300(D1399Y)-myc and 5 µg of CMV-CITED2 using
FuGENE 6 (Roche Molecular Biochemicals). 5 µg of CMV-TFAP2A or the
control vector were also co-transfected. 48 h post-transfection
the cell pellet was lysed for 5 min on ice by adding 5-10 volumes of
lysis buffer (20 mM Tris-HCl, pH 8.0, 20 mM
NaCl, 1 mM DTT, 0.5% Nonidet P-40, 320 mM
sucrose, and Complete protease inhibitor mixture (Roche Molecular
Biochemicals)). The nuclei were then pelleted by centrifugation and
lysed for 30 min on ice by adding 5-10 volumes of nuclei lysis buffer
(20 mM HEPES-KOH, pH 8.0, 420 mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 1 mM DTT, 25% glycerol, and Complete protease inhibitor
mixture (Roche Molecular Biochemicals)). Before the binding assay, the nuclear extracts contained in the supernatant were diluted with two
volumes of 20 mM HEPES-KOH, pH 8.0 containing the Complete protease inhibitor mixture (Roche Molecular Biochemicals). The synthetic oligonucleotide 5'-GATCGAACTGACCGCCCGCGGCCCGT-3'
corresponding to the consensus TFAP2 binding site of the human
metallothionein IIa promoter was end-labeled with
[ p300 and CBP Co-activate TFAP2A Only in the Presence of
CITED2--
To determine whether p300 and CBP act as TFAP2A
co-activators, we transiently co-transfected Hep3B cells (a human
hepatocellular carcinoma cell line that has low levels of endogenous
TFAP2 and CITED2) with a luciferase reporter cloned downstream of TFAP2 binding elements (p3xAP2-Bluc) and vectors expressing TFAP2A, CITED2, CBP, or p300 (Fig.
1A). Under these conditions,
the reporter was mildly activated by the transfection of TFAP2A
expression vector alone. Consistent with our previous results (19),
co-transfection of CMV-CITED2 resulted in further activation of the
reporter, which was dependent on the presence of co-transfected
CMV-TFAP2A. A further increase of the reporter activity (in a
dose-responsive manner) was observed when CBP or p300 expressing
plasmids were co-transfected with both CMV-TFAP2A and CMV-CITED2 (Fig.
1A). CMV-CBP or CMV-p300 showed no effect on
reporter plasmid activity in the absence of co-transfected CMV-TFAP2A
or CMV-CITED2. These results indicate that p300/CBP can co-activate
TFAP2A but only in the presence of CITED2. Similar results were
observed in HepG2 cells, another human hepatocellular carcinoma cell
line (Fig. 1B), indicating that the
CITED2-dependent co-activation of TFAP2A by CBP and p300 is
not restricted to one particular cell line.
p300 and CBP Are Required for TFAP2A Transactivation--
To
determine whether endogenous p300 and CBP are necessary for TFAP2
transactivation, we examined the transcriptional activity of TFAP2
isoforms in MEFs. We isolated MEFs from embryos lacking either
one allele of p300 (p300+/ p300 and TFAP2A Interact Physically--
We next determined
whether p300 and TFAP2A can physically interact in mammalian cells. We
initially attempted to detect TFAP2A in anti-p300 immunoprecipitates.
TFAP2A migrates at ~50 kDa, very close to the immunoglobulin heavy
chain from the immunoprecipitating antibody, and this interfered with
its detection by Western blotting (data not shown). To overcome this,
we transfected U2-OS cells with CMV-p300-myc and CMV-GAL4-TFAP2A.
GAL4-TFAP2A (a fusion of the yeast GAL4 DNA binding domain with TFAP2A)
migrates at 70 kDa, away from the immunoglobulin heavy chain (Fig.
2). We used U2-OS cells as they express
endogenous CITED2 (9). We immunoprecipitated p300-myc from the
transfected cell lysates with an anti-myc antibody (9E10) and detected
co-immunoprecipitated proteins by Western blotting using an
anti-GAL4 antibody (RK5C1). Anti-myc immunoprecipitates from cells
transfected with CMV-p300-myc and CMV-GAL4-TFAP2A contained GAL4-TFAP2A
(Fig. 2A, lane 7) and endogenous CITED2 proteins
(Fig. 2B, lane 7). Control primary antibody
immunoprecipitates from the same cells (Fig. 2, lane 9) did
not contain GAL4-TFAP2A or CITED2. Anti-myc immunoprecipitates from
cells transfected with either CMV-p300-myc or CMV-GAL4-TFAP2A alone
also did not contain GAL4-TFAP2A (Fig. 2A, lanes
8 and 10, respectively). Anti-myc immunoprecipitates
from cells co-transfected with CMV-p300-myc and CMV-GAL4 also did not
contain detectable GAL4 protein (Fig. 2C, lane
12). These results indicate that p300-myc complexes contain both
GAL4-TFAP2A and endogenous CITED2 and that the TFAP2A residues in the
GAL4-TFAP2A fusion protein are required for the interaction.
CITED2 Interacts with the First Helix of the TFAP2 Dimerization
Motif--
To delineate residues of TFAP2 required for the interaction
with CITED2, we used Far Western and yeast two-hybrid assays. We used
35S-labeled TFAP2A, TFAP2B, and TFAP2C protein
probes to determine their ability to bind C-terminal residues of human
CITED2 peptide (residues 234-270), immobilized on nitrocellulose
membranes (Fig. 3A,
panels 1-3). Consistent with previous results
(19), all TFAP2 isoforms bound strongly to CITED2. We next examined the ability of different fragments of TFAP2C to interact with CITED2. The deletion of N-terminal residues 1-219 of TFAP2C
(TFAP2C
We then explored these interactions using yeast two-hybrid assays. Here
we co-expressed GAL4DBD-TFAP2C "baits" with GAL4AD-CITED2 "prey" expression plasmids in yeast cells containing an integrated lacZ reporter downstream of GAL4 binding sites. Consistent
with previous observations (19) we found that GAL4DBD-TFAP2C
full-length bait strongly interacts with a GAL4AD-CITED2 prey
(Fig. 3B). This assay also indicated that the N-terminal
residues 1-180 of TFAP2C (GAL4-TFAP2C The p300-TFAP2A Interaction Requires CITED2--
To determine
whether CITED2 is involved in the recruitment of p300 to TFAP2A, we
used a mammalian two-hybrid assay in Hep3B cells to detect interactions
between the bait p300-E2 (a fusion of p300 with the bovine papilloma
virus E2-DNA binding domain) and the prey VP16-TFAP2A (Fig.
4A). In these experiments we
used a reporter plasmid containing E2 binding sites upstream of the luciferase gene. Transfection of CMV-VP16-TFAP2A alone led to a weak
activation of the reporter and may reflect the presence of cryptic
TFAP2 binding sites in the reporter plasmid. In keeping with previous
observations, transfection of CMV-p300-E2 (with CMV-VP16 control)
activated the luciferase reporter gene (30). A marginal degree of
further activation was observed when CMV-p300-E2 was co-transfected
with the prey plasmid CMV-VP16-TFAP2A, indicating the lack of a
significant two-hybrid interaction between p300-E2 and VP16-TFAP2A.
However, when CMV-CITED2 was co-transfected with CMV-p300-E2 and
CMV-VP16-TFAP2A, a marked increase in the activity of the reporter was
observed, indicating that in the presence of CITED2, VP16-TFAP2A was
able to interact with p300-E2. Co-transfection of CMV-p300-E2,
CMV-VP16, and CMV-CITED2 did not activate the reporter, indicating that
the TFAP2A residues in the VP16-TFAP2A fusion are necessary for the
interaction between VP16-TFAP2A and p300-E2. These results indicate
that CITED2 is necessary for the interaction between full-length TFAP2A
and full-length p300.
The p300-TFAP2A Interaction Requires an Intact p300-CH1
Domain--
To determine the role of the p300-CH1 domain (which is
required for binding CITED2), we also performed these experiments with CMV-p300CH1 Interactions between p300 and TFAP2A Domains That Do Not Require
CITED2--
Certain transcription factors, such as NF-
To further explore CITED2-independent interactions between TFAP2A and
p300, we used GAL4-p300 baits that expressed different fragments of
p300 (Fig. 4C). In these experiments, no interaction was
observed among GAL4 (control bait empty plasmid), GAL4-p300 (residues
1-242) or GAL4-p300 (residues 1737-2414), and VP16-TFAP2A. The N
terminus of p300 (GAL4-p300 residues 1-596 and 1-743) interacted with
the N terminus of TFAP2A (VP16-TFAP2A residues 1-165) but not with
full-length VP16-TFAP2A or the C terminus of TFAP2A (VP16-TFAP2A residues 202-437). This indicates that the isolated N terminus of
TFAP2A can interact with the N terminus of p300, independently of
CITED2. The lack of interaction between full-length TFAP2A and the N
terminus of p300 is not clear but may reflect a structural constraint.
We also found that the C-terminal residues of p300 (GAL4-p300 residues
964-1922) interacted strongly with full-length VP16-TFAP2A and with
VP16-TFAP2A (residues 202-437). These results indicate that the
C-terminal DNA binding and dimerization domains of TFAP2A can interact
with C-terminal residues of p300.
The Transactivation Domain of TFAP2A Is Required for CITED2
Co-activation--
The above results indicated that the N terminus of
TFAP2A, containing the transactivation domain, is both necessary and
sufficient for interaction with full-length p300. This interaction is
independent of CITED2. To determine whether this domain is necessary
for synergistic co-activation by CITED2 and p300, we co-transfected
HepG2 cells with p3xAP2-Bluc and RSV-TFAP2A (expressing full-length
TFAP2A) or RSV-TFAP2A A p300-HAT-deficient Point Mutant (D1399Y) Fails to Co-activate
TFAP2A--
We next determined the ability of a HAT-deficient p300
point mutant (D1399Y) (31) to synergize with CITED2 in co-activating TFAP2A (Fig. 6A). In keeping
with the results described above, co-transfection of CMV-p300-myc with
CMV-TFAP2A led to an increase of the reporter plasmid activity only in
the presence of CMV-CITED2. However, co-transfection of
CMV-p300(D1399Y)-myc failed to stimulate, and in fact appeared to
reduce, transcriptional co-activation of TFAP2A by CITED2. Western
blotting of nuclear extracts from transfected Hep3B cells showed that
p300-myc and p300(D1399Y)-myc are expressed at similar levels (Fig.
6B) and that transfection of p300(D1399Y)-myc did not affect
the expression of either co-transfected TFAP2A or CITED2. Thus the
observed failure of p300(D1399Y)-myc to function as a TFAP2A
co-activator is not because of a simple reduction in expression of
p300, TFAP2A, or CITED2.
p300D1399Y Does Not Affect TFAP2A DNA Binding Activity or CITED2
Nuclear Localization--
In addition to functioning as a histone
acetyltransferase, p300 and CBP can also acetylate transcription
factors and enhance their ability to bind DNA (2). We asked whether the
HAT activity of transfected p300 could affect the DNA binding activity
of co-transfected TFAP2A. We co-transfected Hep3B cells with
CMV-TFAP2A, CMV-CITED2, and with either CMV-p300-myc or
CMV-p300(D1399Y)-myc. We then made nuclear extracts from these cells
and examined their binding to an oligonucleotide containing a high
affinity binding site for TFAP2, by electrophoretic mobility shift
assay (Fig. 6C). In cells transfected with CMV-TFAP2A, we
observed a DNA-protein complex (Fig. 6C, lane 2 and 3, TFAP2A). This was not observed in cells
that were not transfected with TFAP2A (lanes 4, 5 and 6). This DNA-protein complex was efficiently
competed out by a 50-fold molar excess of unlabeled oligonucleotide
(Fig. 6C, lanes 7 and 8), indicating
its specificity for TFAP2 binding sites. No obvious difference was
observed in the TFAP2A-DNA complex in extracts from cells transfected
with CMV-p300-myc or CMV-p300(D1399Y)-myc. These results indicate that
the HAT activity of p300 does not modulate the ability of TFAP2A to
bind DNA.
We next examined the effect of the HAT-deficient p300 mutant on the
subcellular localization of CITED2 and TFAP2A (Fig. 6D). Although the majority of CITED2 localizes to the nucleus, some is
detected in the cytoplasm of transfected Hep3B cells (Fig. 6D, panel c). In cells co-transfected with
CMV-CITED2 and CMV-p300-myc or CMV-p300(D1399Y)-myc (Fig.
6D, panels a and b), CITED2 localized almost exclusively in the nucleus. This result indicated that p300 is
at least in part responsible for the nuclear localization of
CITED2 but that its HAT activity is not required for this nuclear localization. Similarly, we determined the effect of p300 on TFAP2A localization (Fig. 6D, panels e-h).
In Hep3B cells, transfected TFAP2A was detected in the nuclei (Fig.
6D, panel g), and co-transfection of either
CMV-p300-myc or CMV-p300(D1399Y)-myc did not affect TFAP2A localization
(Fig. 6D, panels e and f). These
results indicate that the HAT activity of p300 does not modulate the
cellular localization of TFAP2A or CITED2.
p300D1399Y Does Not Interact with TFAP2A--
We next investigated
the interaction of the p300-HAT-deficient mutant with TFAP2A and
CITED2. We constructed a HAT-deficient version of CMV-p300-E2
(CMV-p300(D1399Y)-E2) and used it in mammalian two-hybrid assays in
Hep3B cells using a reporter plasmid containing E2 binding sites
upstream of the luciferase gene. CMV-p300-E2 and CMV-p300(D1399Y)-E2
were co-transfected in parallel with plasmids expressing VP16-TFAP2A in
the presence or the absence of CMV-CITED2 (Fig.
7A). Transfection of
CMV-p300-E2 resulted in modest reporter gene activation (compared with
CMV-vector control) which was not affected by CITED2. Co-transfection
of VP16-TFAP2A did not affect reporter gene activity in the absence of
CITED2, but in the presence of CITED2 there was a further increase in
reporter activity, indicating a two-hybrid interaction that is
dependent on CITED2. Co-transfection of VP16-TFAP2A (1-165) resulted
in activation of the reporter gene regardless of CITED2
co-transfection. These results are consistent with those shown in Fig.
4A. Transfection of CMV-p300(D1399Y)-E2 led to a smaller
increase of reporter activity compared with CMV-p300-E2, despite being
expressed to a similar level (Fig. 7C), indicating that
HAT-deficient p300 has lower transcriptional activity. No increase in
reporter activity was observed when CMV-p300(D1399Y)-E2 was
co-transfected with CMV-VP16-TFAP2A or CMV-VP16-TFAP2A (1-165), regardless of CMV-CITED2 co-transfection. This result indicated that
the p300-HAT-deficient mutant D1399Y does not interact with either
full-length TFAP2A or with TFAP2A N-terminal residues 1-165.
The p300-HAT-deficient Point Mutant Interacts with
CITED2--
We next determined whether the p300-HAT-deficient
mutant interacts with CITED2. Hep3B cells were co-transfected with
CMV-p300-E2 or CMV-p300(D1399Y)-E2 and CMV-VP16-CITED2 (Fig.
7B). Co-transfection of CMV-VP16-CITED2 with CMV-p300-E2 led
to a ~4.5-fold increase of reporter activity, compared with
CMV-p300-E2 alone, indicating that CITED2 interacts with p300.
Co-transfection of CMV-p300(D1399Y)-E2 with CMV-VP16-CITED2 also led to
a similar -fold increase of the reporter activity compared with the
basal activation because of CMV-p300(D1399Y)-E2, indicating that the
p300-HAT-deficient mutant interacts normally with CITED2.
In this study, we have shown that p300 and CBP can co-activate
TFAP2A and that this co-activation requires the presence of CITED2. Our
experiments show that p300 and CBP heterozygote MEFs display modest
defects in transactivation by TFAP2, which indicate that normal levels
of endogenous p300 and/or CBP are necessary for full transcriptional
activation by TFAP2. The modest impairment in TFAP2 transactivation
observed in heterozygote MEFs is consistent with the fact that the
total complement of p300/CBP is only reduced by one-fourth. The
successful rescue of these defects by ectopically expressed p300 and
CBP indicates that there is no other secondary genetic defect in these
MEFs. Taken together these experiments show that p300/CBP function as
TFAP2 co-activators and that this co-activation critically requires the
presence of another TFAP2 co-activator, CITED2.
We have also shown, using co-immunoprecipitation and mammalian
two-hybrid techniques, that TFAP2A, CITED2, and p300 can interact physically in vivo. This interaction requires the presence
of CITED2 and an intact binding site on p300 for CITED2
(i.e. the CH1 domain). We have also established that CITED2
interacts with residues contained within the first dimerization helix
of TFAP2C. Based on the high conservation of this region among TFAP2
isoforms, showing only conservative changes at three amino acid
positions, and the fact that CITED2 also interacts and co-activates
TFAP2A and TFAP2B (19), we predict that CITED2 also binds to the first dimerization helix of these TFAP2 isoforms.
Our data also show that TFAP2A can interact with certain p300 domains
independently of CITED2. These interactions are summarized in Fig.
8. However, these CITED2-independent
interactions are not sufficient for an interaction between full-length
TFAP2 and full-length p300 and instead may be secondary interactions
that are also required for TFAP2A-mediated transcriptional activation. Significantly, we found that the N terminus of TFAP2A, containing the
transactivation domain, is both necessary and sufficient for interaction with full-length p300. Consistent with this we found that a
TFAP2A peptide lacking N-terminal residues is not successfully co-activated by CITED2 and p300. Taken together, this suggests that the
CITED2-independent interaction between the N termini of TFAP2A and that
of p300 is likely to be functionally significant. An alternative
explanation is that the N terminus of TFAP2A is required to recruit
other co-activators such as PC4 (40) and that these other co-activators
are necessary for CITED2-p300 mediated co-activation of TFAP2A.
and CBP+/
mouse
embryonic fibroblasts; this was rescued by ectopic expression of
p300/CBP. p300, TFAP2A, and endogenous CITED2 could be
co-immunoprecipitated from transfected U2-OS cells indicating that they
can interact physically in vivo. CITED2 interacted with the
dimerization domain of TFAP2C, which is highly conserved in TFAP2A/B.
In mammalian two-hybrid experiments, full-length p300 and TFAP2A
interacted only when CITED2 was co-transfected. N-terminal residues of
TFAP2A, containing the transactivation domain, are both necessary and sufficient for interaction with p300, and this interaction was independent of CITED2. Consistent with this, N-terminal residues of
TFAP2A were required for p300- and CITED2-dependent
co-activation. A histone acetyltransferase-deficient p300 mutant
(D1399Y) did not co-activate TFAP2A and did not affect the expression
or cellular localization of TFAP2A or CITED2. In mammalian two-hybrid
experiments p300D1399Y failed to interact with TFAP2A, explaining, at
least in part, its failure to function as a co-activator. Our results suggest a model wherein interactions among TFAP2A, CITED2, and p300/CBP
are necessary for TFAP2A-mediated transcriptional activation and for
normal neural tube and cardiac development.
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
/
embryos
have reduced expression of the TFAP2 target gene ErbB3 (22) in the
neural crest (19). As TFAP2A and TFAP2B mutations also result in neural
tube, cardiac, and cranial ganglia defects (23-27), it is likely that
abnormal embryonic development in Cited2
/
mice results, at least in part, from defective TFAP2 function (19).
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
N165 were gifts from Trevor Williams (University of
Colorado, Denver, CO). p3xAP2-Bluc was derived from plasmid A2BCAT (29)
and contains three copies of the AP-2 binding site in the human
metallothionein IIa promoter. CMV-p300, CMV-CBP, CMV-p300-E2,
CMV-p300
CH1-E2, and the E2-luc reporter were gifts from Richard
Eckner (University of Zurich, Zurich, Switzerland) (30).
CMV-p300
CH1-E2 lacks residues 346-510 of p300. CMV-p300-myc
and CMV-p300(D1399Y)-myc (containing a point mutation that abolishes
HAT activity (31)) were gifts from Tso-Pang Yao (Duke
University, Durham, NC). An XbaI-XmaI
fragment from p300(D1399Y)-myc was subcloned into CMV-p300-E2 to
generate CMV-p300(D1399Y)-E2. CMV-p300(D1399Y)-E2 was sequenced to
confirm the presence of the point mutation. CMV-VP16-TFAP2A, CMV-VP16-TFAP2A (1-165), and CMV-VP16-TFAP2A (202-437) were gifts from Stefan Gaubatz (University of Marburg, Marburg, Germany). CMV-VP16-CITED2 has been described previously (9). CMV-GAL4 and
CMV-lacZ were gifts from Ronald Evans (Salk Institute, San Diego, CA).
GAL4-p300 fusions (32) were gifts from Antonio Giordano (Thomas
Jefferson University, Philadelphia, PA). pRL-CMV (Renilla luciferase
gene attached to CMV promoter) was from Promega. CMV-GAL4-TFAP2A was
generated by PCR and sequenced to confirm the absence of artifacts. The
yeast vectors expressing GAL4-DBD fused to TFAP2C full-length protein
or subdomains of TFAP2C and the GAL4-AD-CITED2 have been described
previously (19, 33).
-galactosidase (lacZ) activities were measured as
described (28). Renilla luciferase activity was measured using the
DUAL-luciferase reporter assay kit (Promega). The ratio of firefly
luciferase to lacZ or to Renilla luciferase activity (relative
luciferase activity) was calculated to correct for variations in
transfection efficiency. All expression plasmids were driven by the CMV
or the RSV promoter, and an appropriate amount of CMV or RSV control
vector was added to each transfection mix so that the total plasmid
amount and CMV or RSV promoter per transfection were constant for each
experiment. Amounts of DNA used per transfection refer to the amounts
added per well of a 24-well plate.
TriplEx phage
clone encoding the C-terminal residues 234-270 of the human CITED2.
The Escherichia coli strain XL1-Blue was
transduced with the
TriplEx-CITED2 phage and plated at ~100 plaque-forming unit per 10-cm Petri dish, according to the
TriplEx library manual (Clontech PT3003-1). The plates were incubated at
42 °C for 3-4 h until the plaques were just visible and then overlaid with Hybond-C Extra (Amersham Biosciences) membranes, prewetted in 10 mM
isopropyl-
-D-thiogalactopyranoside, and further incubated at 37 °C for another 4 h. The membranes were then removed from the Petri dishes and placed in blocking solution (FW buffer containing 5% dry milk) for 2 h, shaking gently at room
temperature. After blocking, the membranes were placed in FW buffer,
supplemented with an in vitro translated,
35S-labeled protein probe, and incubated overnight at
4 °C, shaking gently. The membranes were washed several times in FW
buffer, and each wash was performed for 30 min at room temperature,
shaking gently. The washed membranes were air-dried and exposed to
BioMax MR-1 (Eastman Kodak Co.) film for several days.
-galactosidase assays were performed according to the
Clontech Matchmaker manual. To verify that TFAP2C
deletion mutants containing the dimerization domain were still able to
self-associate, additional clones were made in pGAD424 to allow this to
be tested in the yeast two-hybrid system (data not shown). For those
mutants that also contained the DNA binding domain, electrophoretic
mobility shift assays were also performed using unlabeled in
vitro translated protein to confirm DNA binding and hence
dimerization (data not shown).
-32P]ATP and T4 polynucleotide kinase and annealed to
a slight excess of the unlabeled complementary strand. Unincorporated
nucleotides were removed using a MicrospinTM G-25 column
(Amersham Biosciences). Unlabeled oligonucleotide was annealed in a
similar manner and used for competition experiments. The DNA binding
reaction was performed in a volume of 25 µl containing 1.5 µg of
nuclear extract, 1 µg of poly(dI-dC)·poly(dI-dC), 25 mM HEPES-KOH, pH 7.9, 150 mM NaCl, 1 mM EDTA, 5 mM DTT, and 10% glycerol. This
mixture was incubated for 10 min on ice before adding 10-15 fmol of
radiolabeled probe. The binding reaction was then carried out for 30 min at room temperature before loading the samples onto a 5%
polyacrylamide gel (37.5:1, acrylamide:bisacrylamide) pre-run for at
least 2 h in 25 mM Tris, pH 8.3, 25 mM
boric acid, 0.5 mM EDTA. Electrophoresis was performed for
2-3 h at 200 V at 4 °C. The gel was dried out and autoradiographed.
For competition experiments, a 50-fold molar excess of unlabeled
oligonucleotide was mixed with the probe before adding nuclear extract.
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
View larger version (29K):
[in a new window]
Fig. 1.
p300 and CBP synergize with CITED2 to
co-activate TFAP2A. A, transcriptional activation of
p3xAP2-Bluc reporter (40 ng) in Hep3B cells by co-transfected
CMV-TFAP2A or the control CMV-vector (60 ng each), CMV-CITED2 or
CMV-vector control (60 ng each), and increasing doses (0, 160, and 320 ng) of CMV-p300 or CMV-CBP. CMV-lacZ (100 ng) was also co-transfected
in each reaction. Results (mean ± S.E. of three independent
experiments) are presented as relative luciferase units
(RLU), corrected for lacZ activity. The control transfection
value (at extreme left) is set at 1. B,
transcriptional co-activation of p3xAP2-Bluc reporter in HepG2 cells
using the conditions described for A. Results are presented
as in A. C, transcriptional activation of
p3xAP2-Bluc reporter (80 ng) by co-transfected CMV-TFAP2 (isoforms
A, B, and C) or the control CMV-vector
(40 ng each) and CMV-p300 or the control CMV-vector (200 ng each) in
p300+/+ and p300+/ MEFs. pRL-CMV plasmid,
expressing Renilla luciferase (20 ng), was also co-transfected in each
reaction. Results (mean ± S.E. of three independent experiments)
are presented as relative firefly luciferase units (RLU),
corrected for Renilla luciferase activity. The control transfection
value (at extreme left) is set at 1. D,
transcriptional activation of p3xAP2-Bluc reporter (80 ng) by
co-transfected CMV-TFAP2 plasmids or the control CMV-vector (40 ng
each) and CMV-CBP or the control CMV-vector (200 ng each) in
CBP+/+ and CBP+/
MEFs. Results are presented
as in C.
) or one allele of CBP
(CBP+/
). We co-transfected the TFAP2 reporter gene and
plasmids expressing TFAP2 isoforms into these MEFs and into wild-type
control MEFs isolated from littermate embryos (Fig. 1, C and
D). As MEFs express CITED2 (9), it was not necessary to also
transfect CITED2 in these experiments. In p300+/
and
CBP+/
MEFs we observed reduced transcriptional activities
of TFAP2A and TFAP2C isoforms (Fig. 1, C and D).
TFAP2B transcriptional activity was also reduced in CBP+/
MEFs (Fig. 1D), whereas only a weak effect was observed in
p300+/
MEFs (Fig. 1C). Co-transfection of p300
and CBP expressing plasmids in p300+/
and
CBP+/
MEFs, respectively, successfully rescued the
defective TFAP2 co-activation (Fig. 1, C and D).
These results indicate that normal levels of endogenous p300 and/or CBP
are necessary for full transcriptional activation by TFAP2.
View larger version (38K):
[in a new window]
Fig. 2.
TFAP2A interacts physically with p300
in vivo. Extracts from U2-OS cells co-transfected
with the indicated plasmids were immunoprecipitated with the indicated
monoclonal antibodies. 9E10 is an anti-myc antibody, RK5C1 is an
anti-GAL4 antibody, and PAB419 is a control antibody. Lanes
1-6 contain 10% of the cell extracts used for
immunoprecipitations shown in lanes 7-12. Panels
A and C show anti-GAL4 immunoblots of the
immunoprecipitation reactions. The position of GAL4-TFAP2A and GAL4
peptides are indicated. The asterisks in panel A
indicate nonspecific immunoprecipitating antibody-related bands.
Panel B shows the anti-CITED2 immunoblot, and the position
of CITED2 is indicated. A longer exposure of the input extracts is also
presented below the main panel (lanes 1-6) to
show endogenous CITED2.
N220) did not affect the interaction with CITED2 (Fig.
3A, panel 4). Deletion of the C-terminal residues
431-450 (TFAP2C
N220C430) also did not affect the interaction (Fig.
3A, panel 5). A further N-terminal deletion that
deleted residues 1-291 (TFAP2C
N292C430) also did not affect the
interaction, but deletion of residues 1-352 (TFAP2C
N353C430)
abrogated the interaction (Fig. 3A, panel 7).
This deletion removes the first helix of the helix-span-helix dimerization domain of TFAP2C (35).
View larger version (40K):
[in a new window]
Fig. 3.
Mapping the CITED2 interaction domain in
TFAP2. A, far Western assay showing the interaction
between the residues 234-270 of CITED2 and the indicated labeled
in vitro translated TFAP2 isoforms. The regions of TFAP2C
used as probes are indicated and named according to the first or last
amino acid remaining after N- or C-terminal deletion, respectively.
B, yeast two-hybrid assay to assess the interaction between
the indicated TFAP2C residues fused to the GAL4-DBD
(GAL4-TFAP2C) and CITED2 fused to the activation domain of
GAL4 (AD-CITED2). FL designates full-length
TFAP2C (residues 1-450). The results are shown as levels of
-galactosidase reporter activity when the GAL4-DBD-TFAP2C plasmids
were co-transformed together with GAL4-AD-CITED2 plasmid over the
background values obtained when the mutants were co-transformed with
the GAL4-AD vector. The
-galactosidase activities (mean ± S.E.
of three independent experiments) are shown. C, summary of
the interactions between TFAP2C and CITED2 detected by FW and yeast
two-hybrid (Y2H) assays. TFAP2C peptide fragments that are
still capable of dimerization are marked with asterisks.
+ indicates the interaction between TFAP2C and CITED2,
and
indicates the lack of interactions between the two
proteins. The TFAP2C domains in the schematic cartoon are indicated as
follows: AD, activation domain; DIM, dimerization
domain.
C181) and the C-terminal
deletion of the second helix of the dimerization domain
(GAL4-TFAP2C
C413) are dispensable for the interaction with CITED2
(Fig. 3B). Compared with the interaction domain defined by
far Western, the only discrepancy was that deletion of the residues
1-291 (GAL4-TFAP2C
N292) failed to interact with AD-CITED2 in yeast
two-hybrid assay. We hypothesize that the fusion of the GAL4-DBD domain
to the residues 292-450 of TFAP2C can lead to the occlusion of the
CITED2 interaction domain in yeast two-hybrid assay. Notably, TFAP2
proteins do not need to be dimers to bind CITED2, as non-dimerizing
mutants (e.g. TFAP2C
N220C413) can still interact (Fig.
3C) (data not shown).
View larger version (29K):
[in a new window]
Fig. 4.
Interactions among TFAP2A,
CITED2, and p300. A, Hep3B cells were
co-transfected with CMV-p300-E2 or CMV-p300 CH1-E2 (40 ng each),
CMV-CITED2 or control plasmid (40 ng each), and CMV-VP16-TFAP2A
(expressing full-length TFAP2A fused to the VP16 activation domain) or
control plasmids (40 ng each), 3xE2-luc reporter (100 ng), and CMV-lacZ
(100 ng). Results (mean ± S.E. of three independent experiments)
are presented as relative luciferase units (RLU), corrected
for lacZ activity. B, Hep3B cells were transfected as
described in A using plasmids expressing TFAP2A residues
1-165 fused to VP16 (CMV-VP16-TFAP2A
(1-165)) or residues 202-437 fused to VP16
(CMV-VP16-TFAP2A (202-437)). C,
a mammalian two-hybrid system was used to assess the interaction of
different GAL4-p300 fusions with VP16-TFAP2A. Hep3B cells were
transfected with plasmids expressing GAL4-p300 domains (40 ng each),
GAL4-luc reporter (100 ng) and CMV-lacZ (100 ng), and CMV-VP16-TFAP2A,
CMV-VP16-TFAP2A (1-165), and residues CMV-VP16-TFAP2A (202-437).
Results are presented as in A. p300 and TFAP2A domains are
indicated in the cartoon as follows: N, N-terminal;
B, bromodomain; Q-rich, glutamine-rich,
AD, activation domain; DIM, dimerization domain
(29, 35, 41, 42).
-E2, which lacks the CH1 domain (Fig. 4A).
Transfection of CMV-p300CH1
-E2 (with CMV-VP16 control) activated the
reporter to the same extent as noted for CMV-p300-E2, and
co-transfection with CMV-VP16-TFAP2A led to a marginal increase in
reporter activity. However, in contrast to the results obtained for
CMV-p300-E2, no increase in reporter activity was noted with
co-transfected CMV-CITED2. This indicates that the p300-CH1 domain is
essential for the CITED2-induced interaction between TFAP2A and p300.
B p65 and
p53, interact with multiple domains of p300/CBP (36-39). To determine whether this is true for TFAP2A, we used a mammalian two-hybrid experiment using different p300-E2 baits and VP16-TFAP2A prey expression constructs (Fig. 4B). In these experiments,
co-transfection of CMV-p300-E2 and N-terminal residues of TFAP2A
(VP16-TFAP2A (1-165)), containing the transactivation domain (29), led
to a marked increase of reporter activity, when compared with
CMV-p300-E2 co-transfected with CMV-VP16 (control prey empty vector;
see Fig. 4B). The level of activation was not affected by
co-transfection of CMV-CITED2. This indicates that an interaction can
occur between p300 and the isolated N terminus of TFAP2A and that this
interaction is independent of CITED2. Notably, the isolated C-terminal
domain of TFAP2A (202-437) did not interact with p300 in this assay
regardless of the presence or absence of CITED2 (Fig. 4B).
Thus, residues 1-201 of TFAP2A (containing the N-terminal
transactivation domain) are essential for interaction with p300.
Co-transfection of p300CH1
-E2 and VP16-TFAP2A (1-165) activated the
reporter construct, indicating that this interaction does not require
the p300-CH1 domain (Fig. 4B).
N165 (expressing a truncated protein lacking
the transactivation domain; see Fig. 5).
Co-transfection of CMV-CITED2 resulted in an increase of the
transcriptional activity of the full-length TFAP2A but failed to
enhance the transcriptional activity of TFAP2A
N165.
Co-transfection of CMV-p300, CMV-CITED2, and RSV-TFAP2A led to a
further increase of the reporter activity, consistent with the results
in Fig. 1. However, co-transfection of CMV-p300, CMV-CITED2, and
RSV-TFAP2
N165 failed to activate the reporter. This result indicated
that co-activation by p300 is not only dependent on CITED2 but also
requires the activation domain of TFAP2A and implies that
CITED2-independent interactions between TFAP2A and p300 may also play
an important role in TFAP2A-mediated transcriptional activation.
View larger version (18K):
[in a new window]
Fig. 5.
The N-terminal domain of TFAP2 is required
for CITED2-mediated co-activation. HepG2 cells were co-transfected
with the 3xAP2-Bluc reporter plasmid (250 ng) and RSV-TFAP2A,
RSV-TFAP2A N165, or the control RSV-vector (50 ng each), CMV-CITED2,
or the CMV-vector control (500 ng each), and with CMV-p300 or the
CMV-vector control (500 ng each). Thymidine kinase
promoter-Renilla (250 ng) was also co-transfected in each reaction.
Results (mean ± S.E. of three independent experiments) are
presented as relative firefly luciferase units (RLU),
corrected for Renilla luciferase activity.
View larger version (49K):
[in a new window]
Fig. 6.
The HAT-deficient p300 mutant (p300D1399Y)
does not co-activate TFAP2A. A, transcriptional
activation of p3xAP2-Bluc reporter (40 ng) in Hep3B cells by
co-transfected CMV-TFAP2A or the control CMV-vector (60 ng each),
CMV-CITED2 and the control CMV-vector (60 ng each), and increasing
doses (0, 160, and 320 ng) of CMV-p300-myc (expressing wild type p300
fused to the myc epitope tag) or CMV-p300(D1399Y)-myc (expressing a
HAT-deficient p300). CMV-lacZ (100 ng) was also co-transfected in each
reaction. Results are presented as for Fig. 1A.
B, Western blots were performed using nuclear extracts
prepared from Hep3B cells transfected with plasmids expressing the
proteins indicated. The relative expression levels of p300-myc
(top panel, lanes 1 and 3),
p300(D1399Y)-myc (top panel, lanes 2 and
4), TFAP2A (lanes 1 and 2), and CITED2
proteins (lanes 1-4), after transfection of the relevant
expression plasmids into Hep3B cells, is compared with untransfected
cells (lane 5). The anti-proliferating cell nuclear antigen
Western blot was performed on the stripped membrane to demonstrate
equal loading. C, electrophoretic mobility shift assays were
performed with nuclear extracts prepared from Hep3B cells transfected
with plasmids expressing the proteins indicated at the top (lanes
2-10) or no protein extract (lane 1). Nuclear extracts
were incubated with a radiolabeled oligonucleotide containing the TFAP2
binding site of the human metallothionein IIa promoter, in the absence
(lane 2-6) or the presence of 50-fold molar excess of
unlabeled competitor oligonucleotide (lanes
7-10). The position of the TFAP2A-DNA complex is
indicated. D, Hep3B cells were co-transfected either with
the plasmids indicated in each panel.
CMV-p300(DY)-myc is an abbreviation for
CMV-p300(D1399Y)-myc, the HAT-deficient mutant. 48 h after
transfection cells were co-immunostained with a monoclonal anti-myc
antibody to detect myc-tagged p300 proteins (red) and with a
polyclonal anti-CITED2 antibody (green; panels
a-d) or with a polyclonal anti-TFAP2A antibody
(green; panels e-h). Nuclei were
counterstained using TOPRO (blue), and cells were examined
by confocal microscopy. The merged image is shown in the
panels on the extreme right.
View larger version (22K):
[in a new window]
Fig. 7.
The HAT-deficient p300 mutant
(p300D1399Y) does not interact with TFAP2A. A,
Hep3B cells were co-transfected with CMV-p300-E2 or the
HAT-deficient mutant CMV-p300(D1399Y)-E2 (40 ng each),
CMV-CITED2 or control plasmid (40 ng each), and CMV-VP16-TFAP2A,
CMV-VP16-TFAP2A (1-165), or control plasmids (40 ng each), 3xE2-luc
reporter (100 ng), and CMV-lacZ (100 ng). Results (mean ± S.E. of
three independent experiments) are presented as relative luciferase
units (RLU), corrected for lacZ activity. B,
Hep3B cells were co-transfected with CMV-p300-E2 or CMV-p300(D1399Y)-E2
(40 ng each), CMV-VP16-CITED2 or control plasmid (40 ng each), and
3xE2-luc reporter (100 ng) and CMV-lacZ (100 ng). Results are presented
as for A. C, top, Western blot showing
relative expression levels of p300-E2 (lane 2) and
p300(D1399Y)-E2 (lane 3) proteins, after transfection of the
relevant expression plasmids into Hep3B cells, compared with
untransfected cells (lane 1). The p300-E2 are produced as
hemagglutinin-tagged proteins and were detected using the mouse
monoclonal 12CA5 antibody as described previously (9).
Bottom, anti-tubulin Western blot to demonstrate equal
loading.
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
View larger version (13K):
[in a new window]
Fig. 8.
Cartoon summarizing interactions among
CITED2, p300, and TFAP2A. This cartoon summarizes the results
obtained in this and previous studies (9, 19). The regions in CITED2
that are conserved in other CITED family members (16) are indicated as
CR1-3.
We also found that a p300-HAT-deficient point mutant (D1399Y) failed to co-activate TFAP2A, suggesting that p300-HAT activity is necessary for TFAP2A co-activation. This mutation did not appear to affect the DNA binding activity, nuclear localization, or protein level of co-transfected TFAP2A. However, the p300D1399Y mutant did not interact with full-length TFAP2A, despite being able to interact with CITED2. This explains, at least in part, its failure to function as a TFAP2A co-activator and suggests that p300-HAT activity may be required for interaction with TFAP2A. Surprisingly, the N-terminal residues of TFAP2A also failed to interact with the p300-HAT mutant. As the N-terminal residues of TFAP2A interact strongly with the isolated N terminus of p300 (also HAT-deficient), one possibility is that in the context of full-length p300, the HAT-deficient mutant has a conformation that precludes binding to TFAP2A.
In summary, our results show that TFAP2A and p300/CBP can interact both
physically and functionally and that these interactions require CITED2.
They also show that p300/CBP and CITED2 are independently required for
full transcriptional activation by TFAP2A. These results are supported
by the observation that a HAT-deficient p300 point mutation fails to
co-activate and interact with TFAP2A and that cells lacking an allele
of either p300 or CBP display TFAP2 transactivation defects. Our
results suggest a model wherein interactions among TFAP2A, CITED2, and
p300/CBP are necessary for TFAP2A-mediated transcriptional activation.
In experiments presented here and elsewhere, we showed that CITED2
binds directly to p300/CBP and also to TFAP2 isoforms independently of
its interaction with p300 and CBP (9, 19). A simple model is that
CITED2 acts as a bridge, linking TFAP2A to p300/CBP. Alternatively,
interactions with CITED2 may lead to modifications in p300/CBP and/or
TFAP2A, allowing them to interact. Taken together, these results
support the idea that physical and functional interactions among
p300/CBP, CITED2, and TFAP2A are essential for normal neural tube and
cardiac development and that certain aspects of p300 and CBP
haploinsufficiency (Rubinstein-Taybi syndrome) result from defective
TFAP2 function.
![]() |
ACKNOWLEDGEMENTS |
---|
We are grateful to David Livingston, Richard Eckner, Tso-Pang Yao, Stefan Gaubatz, Trevor Williams, and Ronald Evans for generously providing reagents.
![]() |
FOOTNOTES |
---|
* This work was supported by the Wellcome Trust and Cancer Research UK.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
¶ Wellcome Trust Senior Research Fellow in Clinical Science. To whom correspondence should be addressed. Tel.: 44-1865-287581; Fax: 44-1865-287661; E-mail: sbhattac@well.ox.ac.uk.
Published, JBC Papers in Press, February 12, 2003, DOI 10.1074/jbc.M208144200
![]() |
ABBREVIATIONS |
---|
The abbreviations used are: CREB, cAMP-response element-binding protein; AD, activation domain; CBP, CREB-binding protein; CH, cysteine-histidine-rich domain of p300; CMV, cytomegalovirus; DBD, DNA binding domain; FW, Far Western; HAT, histone acetyltransferase; luc, firefly luciferase gene; MEFs, mouse embryonic fibroblasts; TFAP2, transcription factor AP-2; RSV, Rous sarcoma virus; DTT, dithiothreitol.
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
1. |
Chan, H. M.,
and La Thangue, N. B.
(2001)
J. Cell Sci.
114,
2363-2373 |
2. |
Kouzarides, T.
(2000)
EMBO J.
19,
1176-1179 |
3. |
Oike, Y.,
Takakura, N.,
Hata, A.,
Kaname, T.,
Akizuki, M.,
Yamaguchi, Y.,
Yasue, H.,
Araki, K.,
Yamamura, K.,
and Suda, T.
(1999)
Blood
93,
2771-2779 |
4. |
Oike, Y.,
Hata, A.,
Mamiya, T.,
Kaname, T.,
Noda, Y.,
Suzuki, M.,
Yasue, H.,
Nabeshima, T.,
Araki, K.,
and Yamamura, K.
(1999)
Hum. Mol. Genet.
8,
387-396 |
5. | Yao, T. P., Oh, S. P., Fuchs, M., Zhou, N. D., Ch'ng, L. E., Newsome, D., Bronson, R. T., Li, E., Livingston, D. M., and Eckner, R. (1998) Cell 93, 361-372[Medline] [Order article via Infotrieve] |
6. | Petrij, F., Giles, R. H., Dauwerse, H. G., Saris, J. J., Hennekam, R. C. M., Masuno, M., Tommerup, N., Ommen, G. B., Goodman, R. H., Peters, D. J. M., and Breuning, M. H. (1995) Nature 376, 348-351[CrossRef][Medline] [Order article via Infotrieve] |
7. | Kawasaki, H., Eckner, R., Yao, T. P., Taira, K., Chiu, R., Livingston, D. M., and Yokoyama, K. K. (1998) Nature 393, 284-289[CrossRef][Medline] [Order article via Infotrieve] |
8. |
Bordoli, L.,
Husser, S.,
Luthi, U.,
Netsch, M.,
Osmani, H.,
and Eckner, R.
(2001)
Nucleic Acids Res.
29,
4462-4471 |
9. |
Bhattacharya, S.,
Michels, C. L.,
Leung, M. K.,
Arany, Z. P.,
Kung, A. L.,
and Livingston, D. M.
(1999)
Genes Dev.
13,
64-75 |
10. | Leung, M. K., Jones, T., Michels, C. L., Livingston, D. M., and Bhattacharya, S. (1999) Genomics 61, 307-313[CrossRef][Medline] [Order article via Infotrieve] |
11. |
Yahata, T.,
de Caestecker, M. P.,
Lechleider, R. J.,
Andriole, S.,
Roberts, A. B.,
Isselbacher, K. J.,
and Shioda, T.
(2000)
J. Biol. Chem.
275,
8825-8834 |
12. |
Newton, A. L.,
Sharpe, B. K.,
Kwan, A.,
Mackay, J. P.,
and Crossley, M.
(2000)
J. Biol. Chem.
275,
15128-15134 |
13. |
Shioda, T.,
Fenner, M. H.,
and Isselbacher, K. J.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
12298-12303 |
14. | Dunwoodie, S. L., Rodriguez, T. A., and Beddington, R. S. P. (1998) Mech. Dev. 72, 27-40[CrossRef][Medline] [Order article via Infotrieve] |
15. |
Sun, H. B.,
Zhu, Y. X.,
Yin, T.,
Sledge, G.,
and Yang, Y. C.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
13555-13560 |
16. |
Braganca, J.,
Swingler, T.,
Marques, F. I.,
Jones, T.,
Eloranta, J. J.,
Hurst, H. C.,
Shioda, T.,
and Bhattacharya, S.
(2002)
J. Biol. Chem.
277,
8559-8565 |
17. | Yahata, T., Takedatsu, H., Dunwoodie, S. L., Braganca, J., Swingler, T., Withington, S. L., Hur, J., Coser, K. R., Isselbacher, K. J., Bhattacharya, S., and Shioda, T. (2002) Genomics 80, 601-613[CrossRef][Medline] [Order article via Infotrieve] |
18. |
Yahata, T.,
Shao, W.,
Endoh, H.,
Hur, J.,
Coser, K. R.,
Sun, H.,
Ueda, Y.,
Kato, S.,
Isselbacher, K. J.,
Brown, M.,
and Shioda, T.
(2001)
Genes Dev.
15,
2598-2612 |
19. | Bamforth, S. D., Braganca, J., Eloranta, J. J., Murdoch, J. N., Marques, F. I., Kranc, K. R., Farza, H., Henderson, D. J., Hurst, H. C., and Bhattacharya, S. (2001) Nat. Genet. 29, 469-474[CrossRef][Medline] [Order article via Infotrieve] |
20. |
Barbera, J. P.,
Rodriguez, T. A.,
Greene, N. D.,
Weninger, W. J.,
Simeone, A.,
Copp, A. J.,
Beddington, R. S.,
and Dunwoodie, S.
(2002)
Hum. Mol. Genet.
11,
283-293 |
21. |
Yin, Z.,
Haynie, J.,
Yang, X.,
Han, B.,
Kiatchoosakun, S.,
Restivo, J.,
Yuan, S.,
Prabhakar, N. R.,
Herrup, K.,
Conlon, R. A.,
Hoit, B. D.,
Watanabe, M.,
and Yang, Y. C.
(2002)
Proc. Natl. Acad. Sci. U. S. A.
99,
10488-10493 |
22. | Skinner, A., and Hurst, H. C. (1993) Oncogene 8, 3393-3401[Medline] [Order article via Infotrieve] |
23. | Zhang, J., Hagopian-Donaldson, S., Serbedzija, G., Elsemore, J., Plehn-Dujowich, D., McMahon, A. P., Flavell, R. A., and Williams, T. (1996) Nature 381, 238-241[CrossRef][Medline] [Order article via Infotrieve] |
24. | Schorle, H., Meier, P., Buchert, M., Jaenisch, R., and Mitchell, P. J. (1996) Nature 381, 235-238[CrossRef][Medline] [Order article via Infotrieve] |
25. | Satoda, M., Zhao, F., Diaz, G. A., Burn, J., Goodship, J., Davidson, H. R., Pierpont, M. E., and Gelb, B. D. (2000) Nat. Genet. 25, 42-46[CrossRef][Medline] [Order article via Infotrieve] |
26. | Zhao, F., Weismann, C. G., Satoda, M., Pierpont, M. E., Sweeney, E., Thompson, E. M., and Gelb, B. D. (2001) Am. J. Hum. Genet. 69, 695-703[CrossRef][Medline] [Order article via Infotrieve] |
27. | Brewer, S., Jiang, X., Donaldson, S., Williams, T., and Sucov, H. M. (2002) Mech. Dev. 110, 139-149[CrossRef][Medline] [Order article via Infotrieve] |
28. | Ausubel, F., Brent, R., Kingston, R. E., Moore, D. D., Seidman, J. G., Smith, J. A., and Struhl, K. (1995) Short Protocols in Molecular Biology , 3rd Ed. , John Wiley & Sons, Inc., New York |
29. | Williams, T., and Tjian, R. (1991) Genes Dev. 5, 670-682[Abstract] |
30. | Arany, Z., Newsome, D., Oldread, E., Livingston, D. M., and Eckner, R. (1995) Nature 374, 81-84[CrossRef][Medline] [Order article via Infotrieve] |
31. |
Ito, A.,
Lai, C. H.,
Zhao, X.,
Saito, S.,
Hamilton, M. H.,
Appella, E.,
and Yao, T. P.
(2001)
EMBO J.
20,
1331-1340 |
32. |
Yuan, W.,
Condorelli, G.,
Caruso, M.,
Felsani, A.,
and Giordano, A.
(1996)
J. Biol. Chem.
271,
9009-9013 |
33. |
Eloranta, J. J.,
and Hurst, H. C.
(2002)
J. Biol. Chem.
277,
30798-30804 |
34. | Loo, D., Rawson, C., Ernst, T., Shirahata, S., and Barnes, D. (1989) in Cell Growth and Division: A Practical Approach (Baserga, R., ed) , pp. 17-35, Oxford University Press, Oxford |
35. | Williams, T., and Tjian, R. (1991) Science 251, 1067-1071[Medline] [Order article via Infotrieve] |
36. | Zhong, H., Voll, R. E., and Ghosh, S. (1998) Mol. Cell 1, 661-671[Medline] [Order article via Infotrieve] |
37. | Grossman, S. R., Perez, M., Kung, A. L., Joseph, M., Mansur, C., Xiao, Z. X., Kumar, S., Howley, P. M., and Livingston, D. M. (1998) Mol Cell 2, 405-415[Medline] [Order article via Infotrieve] |
38. | Gu, W., Shi, X. L., and Roeder, R. G. (1997) Nature 387, 819-823[CrossRef][Medline] [Order article via Infotrieve] |
39. | Avantaggiati, M. L., Ogryzko, V., Gardner, K., Giordano, A., Levine, A. S., and Kelly, K. (1997) Cell 89, 1175-1184[Medline] [Order article via Infotrieve] |
40. |
Kannan, P.,
and Tainsky, M. A.
(1999)
Mol. Cell. Biol.
19,
899-908 |
41. | Eckner, R., Ewen, M. E., Newsome, D., Gerdes, M., DeCaprio, J. A., Lawrence, J. B., and Livingston, D. M. (1994) Genes Dev. 8, 869-884[Abstract] |
42. |
Wankhade, S., Yu, Y.,
Weinberg, J.,
Tainsky, M. A.,
and Kannan, P.
(2000)
J. Biol. Chem.
275,
29701-29708 |